Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Zendy

Naiyer A. Rizvi | Zendy; Julien Mazières | Zendy; David Planchard | Zendy; Thomas E. Stinchcombe | Zendy; Grace K. Dy | Zendy; Scott J. Antonia | Zendy; Leora Horn | Zendy; H. Léna | Zendy; Elisa Minenza | Zendy; B. Mennecier | Zendy; Gregory A. Otterson | Zendy; Luis T. Campos | Zendy; David R. Gandara | Zendy; Benjamin Levy | Zendy; Suresh Nair | Zendy; Gérard Zalcman | Zendy; Jürgen Wolf | Zendy; Pierre-Jean Souquet | Zendy; Editta Baldini | Zendy; Federico Cappuzzo | Zendy; C. Chouaïd | Zendy; Afshin Dowlati | Zendy; Rachel E. Sanborn | Zendy; Ariel López-Chávez | Zendy; Christian Grohé | Zendy; Rudolf M. Huber | Zendy; Christopher Harbison | Zendy; Christine Baudelet | Zendy; Brian Lestini | Zendy; Suresh S. Ramalingam | Zendy

Open Access

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Author(s) -

Naiyer A. Rizvi,

Julien Mazières,

David Planchard,

Thomas E. Stinchcombe,

Grace K. Dy,

Scott J. Antonia,

Leora Horn,

H. Léna,

Elisa Minenza,

B. Mennecier,

Gregory A. Otterson,

Luis T. Campos,

David R. Gandara,

Benjamin Levy,

Suresh Nair,

Gérard Zalcman,

Jürgen Wolf,

Pierre-Jean Souquet,

Editta Baldini,

Federico Cappuzzo,

C. Chouaïd,

Afshin Dowlati,

Rachel E. Sanborn,

Ariel López-Chávez,

Christian Grohé,

Rudolf M. Huber,

Christopher Harbison,

Christine Baudelet,

Brian Lestini,

Suresh S. Ramalingam

Publication year - 2015

Publication title -

carolina digital repository (university of north carolina at chapel hill)

Language(s) - English

DOI - 10.17615/74ry-7003

Subject(s) - nivolumab , refractory (planetary science) , medicine , cancer research , oncology , lung cancer , cancer , immunotherapy , materials science , composite material

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research